山東新華制藥股份有限公司

          山東新華制藥股份有限公司（簡稱新華制藥）是H股、A股上市公司，1943年建廠，全國醫(yī)藥行業(yè)50強(qiáng)，8個(gè)原料藥通過了美國FDA，10個(gè)API獲得了歐洲COS證書。新華醫(yī)藥集團(tuán)也從事化工品的生產(chǎn)，用于我公司原料藥的合成，并可廣泛用于其他行業(yè)，例如：、顏料中間體、PVC穩(wěn)定劑等。新華制藥的化工品業(yè)務(wù)由進(jìn)出口公司負(fù)責(zé)，生產(chǎn)基地占地2800畝，化工產(chǎn)品年生產(chǎn)總量43萬噸，DBU(二氮雜二環(huán))、四甲基胍、6-氨基-1,3-二甲基尿嘧啶、1-基-3-甲基-5-吡唑啉酮等為主導(dǎo)產(chǎn)品，其中四甲基胍、二氮雜二環(huán)獲山東省高新技術(shù)產(chǎn)品認(rèn)證并得到國家專利。
       Shandong Xinhua Pharmaceutical Co., Ltd. (the company) is a public company listed in HongKong Stock Exchange and Shenzhen Stock Exchange, now is a leading pharmaceutical company has a history of more than 70 years in pharmaceutical community ,with FDA proved facility for 8 APIs and COS certificate for 10 APIs. The company also has fine chemicals, which are used in our API synthesis and widely used in many other kinds of industries, such as agrochemicals, dyestuff, PVC ... [詳細(xì)介紹]